**Simon P. Weisenhorn**

spweisen@ncsu.edu | (704) 666-0010 | www.linkedin.com/in/simon-weisenhorn-stat

|  |
| --- |
| **EDUCATION** |

**North Carolina State University** – Raleigh, NC December 2023

*Master of Statistics*

* Taken courses at the PhD level instead of the Master level

**University of North Carolina at Chapel Hill** – Chapel Hill, NC May 2022

*B.S., Statistics and Analytics*

*Data Science Minor*

* GPA: 3.485
* Relevant Coursework: Advanced Methods of Data Analysis, Data Science, Stochastic Modeling, Probability, Optimization, Linear Algebra, and Multiple Variable Calculus

|  |
| --- |
| **EXPERIENCE** |

**Catalyst Clinical Research** – Raleigh, NC                                    May 2020 – Present

*Biostatistician Intern; Contract research organization providing multi-therapeutic resourcing and cancer therapies*

* Assisted lead project statistician in several different clinical trials including:
  + A Phase I Study on Healthy Patients to Determine the Pharmacodynamic, Pharmacokinetics and Safety of Multiple Doses of Intranasal and Intravenous Ketamine in Normal Healthy Volunteers
    - Quality Control (QC) of the PD/PK portion of the clinical study report (CSR)
    - Confirmed statistical results were entered correctly from the study tabulations and figures by the lead statistician
    - Checked report for grammatical errors
  + A Proof-of-Concept, Open-Label Study, Evaluating the Safety and Tolerability of Cilofexorin in Subjects with Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
    - Validated study listings using SAS version 9.4 on a Windows based platform
    - Reprogrammed listings for an independent validation
  + A Phase II Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults. This NIH adaptive trial aims to streamline the pathway to finding urgently needed COVID-19 treatments by repurposing either licensed or late-stage-development medicines and testing them in a way that identifies the most promising agents for a Phase III study in the most expedient way possible.
  + A Prospective, Open-Label, Dose-Escalation Phase I Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulate for the Treatment of Knee Osteoarthritis
  + A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a New Drug in Infants and Young Children with Achondroplasia
    - Annotated all of the case report form documents for the programmers to reference
  + A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of a New Drug in Subjects with Select Advanced Solid Tumors Who Have Received up to Five Lines of Prior Therapies
    - Addressed client comments on outputs and dataset programs
* Read and conformed with Catalyst Standard Operating Procedures (SOPs)
* Programmed listings and tables from CDISC (Clinical Data Interchange Standards Consortium) data sets including both SDTM (Study Data Tabulation Model) and ADaM (Analysis Dataset Model)

**PERSONAL PROJECT**

**Personal Website**  February 2021 – Present

* Programmed and designed a website in R using the blogdown package
* Focuses on showcasing recent and future class assignments as well as my work experiences
* www.simonweisenhorn.com

|  |
| --- |
| **ADDITIONAL INFORMATION** |

* Proficient in R, SAS, CSS, and HTML
* Familiar with Python and Java
* Interests: Backpacking, Fishing, Kayaking, and Traveling